Elevation of baseline C-reactive protein (CRP) is associated with increased
Introduction
C-reactive protein (CRP) is a 110 kDa protein made up of five identical subunits. 1 In the presence of Ca ++ it binds phosphocholine with high affinity, 2 but other ligands including phosphatidylethanolamine, chromatin, histones, the 70 kDa polypeptide of the U1 small nuclear ribonucleoprotein, nuclear envelope protein, fibronectin, and laminin are also bound. 3, 4 Ligand-bound CRP activates the classical pathway of complement, 5 and the protein is recognized by Fc␥RI and Fc␥RII. 6, 7 Consequently CRP effects a host defense function mediated at least in part through the elimination of pathogens. 8, 9 In addition CRP promotes the clearance of apoptotic cells, 10 an effect that likely contributes to homeostasis in systemic autoimmune diseases. 11 Notably, although this prototypical serum acute phase protein is the strongest univariate predictor of the risk of future cardiovascular events in healthy adults, 12 only subtle elevation in baseline concen-tration of CRP is required to significantly increase the cardiovascular disease risk. 12, 13 It has been proposed, but not proven, that these small differences in baseline CRP reflect sub-clinical vascular inflammation. 12 Serum CRP is routinely measured as a marker of inflammation in a variety of diseases and its level usually correlates with that of IL6. 14 However, in the autoimmune disease systemic lupus erythematosus (SLE) there is often low CRP despite an increase in IL6. 15 In fact elevation of CRP helps distinguish bacterial infection from active SLE. 16 These observations raise the possibility that CRP, and perhaps its regulation, plays an important role in SLE. As already pointed out, CRP binds to a variety of potential nuclear autoantigens 3, 4, [17] [18] [19] and promotes clearance of apoptotic bodies. 10, 11 Of further relevance is the observation that CRP can mediate in vitro the complement-dependent solubilization of chromatin, 20 and that human CRP administered to mice alters the plasma clearance of injected nucleosome core-particles and chromatin. 21, 22 Moreover, injected CRP offers some protection to lupus prone (NZB×NZW) F1 mice immunized with chromatin, 21 and CRP transgenic (NZB×NZW) F1 mice have delayed onset of disease and significantly extended lifespan compared to non-transgenic littermates. 23 The fact that regulation of the human CRP transgene is sex steroid dependent 24 adds additional interest to the role of CRP in SLE because of the marked female predominance of many autoimmune diseases. The aberrant regulation of CRP during SLE flares and the key role of CRP in animal models of lupus suggests that CRP might be an important candidate gene in SLE. In this context, CRP is found in immune complexes purified from the sera of SLE patients, 25 and family studies have demonstrated important genetic influences in SLE with linkage to several regions on human chromosome 1. [26] [27] [28] The CRP gene is located on chromosome 1q23 29 and is proximal to or within at least one of these candidate linkage regions.
The single CRP gene consists of two exons and one intervening intron that contains a polymorphic (GT) n repeat. 30, 31 At least nine different alleles were identified in a small group of healthy European Caucasians, 32 but it is not known if the representation of (GT) n alleles differs among races or between healthy and diseased populations. Also, it is not known whether the different alleles affect baseline CRP levels. Therefore, we evaluated the CRP gene (GT) n polymorphism in relation to race, baseline levels of CRP, and the clinical phenotype of SLE. Our results show that: (1) the distribution of alleles differs significantly among the races; (2) differences in alleles are associated with differences in baseline CRP within the races; and (3) CRP is not a disease risk factor in SLE.
Results

CRP polymorphism Thirteen alleles of the (GT)
n microsatellite within the intron of the CRP gene were identified ( Figure 1 ). These n polymorphism in controls and SLE patients was determined for Caucasians (a) and African-Americans (b). Note break in ordinate axes and change in scale.
Genes and Immunity ranged in length from 162 to 194 bp, corresponding to introns containing nine to 25 repeats (GT 9 to GT 25 ). Two of these (GT 16 and GT
21
) accounted for Ͼ75% of all the alleles identified (Figure 1 ). Caucasian and AfricanAmerican controls (Figure 1a and b) had significantly different CRP allele frequencies ( 2 = 206, P Ͻ 0.0001, df = 7). This difference was due to increased frequency of intermediate-length alleles (GT 17 -GT 20 ) in African-Americans, which causes a compensatory two-fold lower frequency of GT 16 and GT 21 in this race (36.4% and 9.8%) compared with Caucasians (62.8% and 24.2%). There was no significant difference in CRP allele frequencies between controls vs race-matched SLE patients ( Figure 1 ).
The CRP alleles represented 38 different genotypes, and the genotype frequencies in the control and affected populations did not deviate from their expected value by Hardy-Weinberg equilibrium. Thus, as predicted from their allele distributions (Figure 1 ), the genotype frequencies differed markedly between Caucasians and African-Americans but not between controls and racematched SLE patients ( Figure 2 ). Importantly, the three most common genotypes (GT 16/16 , GT 16/21 , and GT 21/21 ) accounted for 78% of all Caucasians (patients + controls) but only 20% of all African-Americans.
CRP baseline levels and genetic polymorphism
Before testing if CRP genotype affected CRP baseline level, we performed stepwise regression analysis to identify potentially confounding variables. When age, race, sex, and disease status were used as independent variables, this analysis suggested that age had a minimal but significant effect on CRP values (r 2 = 0.043, P Ͻ 0.001). In fact as shown in Figure 3 , baseline CRP was correlated with age-groups in both the healthy (ANOVA: F = 4.14, P = 0.0012, df = 5) and diseased population (F = 2.28, P = 0.048, df = 5). All subsequent analyses of baseline levels was performed on CRP values adjusted to account for this age effect, where the adjusted CRP value = CRP value − (age in years × 0.073).
Initially to obtain evidence that the number of GT repeats influences baseline CRP levels, we investigated homozygous individuals irrespective of their disease status. Compared to individuals with the two most common genotypes (GT 16/16 and GT 21/21 ; see Figure 2 ), baseline CRP was significantly higher in GT 18/18 and GT 20/20 homozygotes (ANOVA: F = 4.08, P = 0.0185, df = 2; Figure 4 ). The GT 16 and GT 21 alleles were thus functionally equivalent ( Figure 4 ) and we predicted that CRP serum levels in GT 16/21 heterozygotes would mirror those in GT 16/16 and GT 21/21 homozygotes. To test this hypothesis we re-analyzed the relationship between allele size and baseline CRP level using only those individuals that carried at least one copy of the common GT 16 allele. These accounted for 74.9% of all subjects. As predicted, baseline CRP levels in GT 16/16 and GT 16/21 individuals were not significantly different (t-test, P = 0.3973; Figure 5a ). Interestingly of various regression models tested, the relationship between baseline CRP and CRP genotype was described best by a sine-wave model with a periodicity of five GT-repeats (Figure 5a ). This model also was a bestfit when African-Americans and Caucasians were analyzed separately (Figure 5b and c) .
Finally to examine potential interactions between CRP genotype, baseline CRP, and disease status, the GT 16 and x/x individuals carry none. The frequencies of the CRP low genotypes were significantly different among the races for both the control ( 2 = 74.8, P Ͻ 0.0001, df = 4) and affected populations ( 2 = 54.9, P Ͻ 0.0001, df = 4), but within each race there was no significant difference between patients and controls (Table 1) . Importantly as shown in Figure 6 , the number of CRP low alleles did affect CRP baseline values. Baseline CRP decreased significantly as the number of CRP low alleles increased in SLE patients (ANOVA; F = 5.804, P = 0.0035, df = 2) but not in controls ( Figure 6 ). Consequently for individuals with no CRP low alleles or only one, baseline CRP was elevated in SLE compared with allele-matched controls ( Figure 6 ). In contrast there was no difference in the CRP levels in healthy vs diseased donors carrying two CRP low alleles ( Figure 6 ). Since 44% of all patients carry two CRP low alleles ( Figure 6 ) this might explain the reported variability in CRP responses of SLE patients.
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Discussion
The number of CRP alleles that we identified and their frequency distribution corresponds closely to that reported by Weber et al, 32 who found nine alleles in a cohort of 57 unrelated European Caucasians. However, ours is the first study to compare CRP allele distribution among races and between healthy and diseased subjects, and to investigate systematically the association between CRP polymorphism and CRP expression. We found that allele frequency for the CRP polymorphism is significantly different between African-Americans and Caucasians. The frequency distribution of CRP alleles (Figure 1) suggests that the short and presumably more stable allele, GT 16 , pre-existed in all the populations and that the larger less stable alleles, GT 17 -GT 25 , arose first in African- Americans. The extent of polymorphism does not differ between healthy subjects and those with SLE, nevertheless different CRP alleles are associated with differences in baseline CRP. These results strongly suggest that baseline CRP has a genetic component. This is in accordance with a recent family study also concluding that CRP levels are determined at least partially by genetic factors. 33 The finding is important given that in myocardial infarction for example, there is increased risk of disease in patients with only modestly elevated baseline CRP. 12, 13 Perhaps our results might help understand the link between raised levels of CRP and a family history of myocardial infarction. 34 The exact mechanism by which the CRP polymorphism influences CRP gene expression is not yet known, but logical models can be entertained. The GT low alleles could of course be in linkage with an as yet unidentified element(s) in the proximal promoter region of the CRP gene, and we are currently investigating this possibility. On the other hand growing evidence suggests that sequence changes in the introns of other genes (IL-1␤, TNF␣, INF␥) also associate with differences in production of the corresponding protein. [35] [36] [37] Thus the intron per se might participate directly in CRP regulation, but how? We think it is important that the two CRP low alleles we identified differ in length by exactly 10 bp. GT repeats are known to affect DNA structure, 10 bp is sufficient for one complete turn of helical double-stranded DNA, 38 and inspection of the CRP gene sequence reveals that the (GT) n region disrupts a consensus sequence for the hormone response element HRE-3. 39 HRE-3 has the dyad sequence AGAACAxxxTGTTTC while the CRP intron contains the sequence AGAACAx 17 (GT) n x 26 TGTTC. Perhaps then the length of the (GT) n linker influences the conformation of the CRP intron and consequently the orientation of the flanking HRE-3 half-sites. According to this conjecture the (GT) n polymorphism presumably directly affects the ability of HRE-3 to interact with a trans-acting factor normally required to depress CRP expression. The appeal of this model is that it accounts for the sine-wave symmetry we observed for CRP expression. Furthermore although the gradual increase in baseline CRP with age might simply reflect biologic aging, 40 this could be related to the operation of the hormone-response element in the GT low allele.
Based on the mounting evidence for a beneficial role of CRP in SLE, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] one would predict that the protein's protective capacity might correlate with its baseline level. Our observation that African-Americans carry fewer CRP low alleles than Caucasians might initially seem at odds with this hypothesis, as African-Americans are known to have a disproportionately higher incidence of SLE. 41 However, if CRP contributes to the pathogenesis of SLE at all, it likely acts as a disease modifying factor rather than a disease risk factor. This could explain the preferential association of Fc␥RIIa alleles (a CRP receptor) with SLE in African-Americans. 42, 43 Whether CRP low alleles are associated with reduced risk of myocardial infarction is clearly worth investigating.
Materials and methods
Subjects
The Carolina Lupus Study (CLU), a population-based case-control study of risk factors for SLE, was conducted in 60 counties in North and South Carolina between 1997 and 1999. Patients were identified through 30 community-based and four university-based rheumatology practices. To be included in the study each patient had to fulfill the 1997 American College of Rheumatology classification criteria for SLE, be diagnosed between 1 January 1995 and 31 July 1999, and be at least 18 years old. Age-, sex-, and community-matched healthy controls were identified using driver's license records. Their eligibility criteria included never having been diagnosed with lupus of any sort. This study was approved by the review board of all participating institutions.
The median time from diagnosis of SLE to entry of patients was 13 months. All participants were interviewed in person and asked to provide a blood sample. Typically for patients their disease was quiescent at the time of phlebotomy. Blood was obtained from 244 cases (92% of all recruits) and 302 controls (85%). One case and two controls did not give permission for genetic testing, DNA was not available for three cases and 24 controls, and only DNA was available from one patient. Thus the CRP polymorphism and expression data described here are based on the 546 subjects in Table 2 .
CRP baseline level and genotype determination
White blood cells were isolated and the associated serum was collected. Serum CRP was measured by ELISA 8 with a lower limit of detection of Ͻ20 ng human CRP/ml serum. Genomic DNA was extracted from white blood cells by proteinase K digestion and salting out. Molecular typing at the CRP intron (GT) n polymorphism was done by PCR 32 followed by use of sequencer and Genescan software. Amplification was done using primers that flanked the (GT) n repeat region: 5′-6FAM-GTATGAACA-GAACAGTGGAGCATCCT-3′ and 5′-CCAGAAAAA-CAAGCAAATGTGAGAG-3′ (Perkin-Elmer, Norwalk, CT, USA). An aliquot of the amplified product was run on a 1.5% agarose gel to verify its integrity, and the sample was electrophoresed on a long-range polyacrylamide gel on a 377 DNA sequencer (ABI-PRISM, PE Biosystems, CA, USA). Raw data were collected and the molecular weight of each amplification product was interpolated using Genescan 2.0.2 software and Genescan-500 Rox size standards (ABI-PRISM). The length of the PCR products ranged from 162 to 194 bp, corresponding to introns containing nine to 25 repeats (GT 9 to GT 25 ). The CRP intron was successfully amplified from 511 of 519 (97.3%) of the DNA samples tested.
Statistical analysis
Continuous variables with highly skewed frequency distributions (CRP, variance/mean = 8.47; age, variance/ mean = 5.13) were log-transformed to achieve a normal distribution prior to parametric testing. Comparison between groups of continuous variables was done using Student's t-tests and ANOVA. After combining groups to ensure minimum expected values greater than 5, allele frequencies and the influence of categorical genotype groups were compared using 2 tests with Fisher's correction. The relationship between CRP genotype and CRP baseline values was analyzed using stepwise and nonlinear regression analysis. All analyses were performed using Statview  5 version 5.0.1 (SAS Institute, Cary, NC, USA) and P Ͻ 0.05 was considered significant in all tests.
